Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01634555 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Pharmacokinetics of Ramucirumab (IMC-1121B) in Combination With FOLFIRI
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
NCT01634555 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 29 participants.
The verdict
NCT01634555, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the effect of concomitant ramucirumab (IMC-1121B) on the pharmacokinetics of irinotecan and its metabolite SN-38 when coadministered with folinic acid and 5-fluorouracil, in participants with advanced malignant solid tumors resistant to standard therapy or for which no standard therapy is available.
Interventions
- DRUG Irinotecan
- DRUG 5-Fluorouracil
- DRUG Folinic acid
- BIOLOGICAL Ramucirumab (IMC-1121B)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2012-10 |
| Est. Completion | 2018-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01634555
The ClinicalTrials.gov registry entry for NCT01634555 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Irinotecan is the first listed.
NCT01634555 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01634555 about?
NCT01634555 is a clinical study titled "A Study to Assess the Pharmacokinetics of Ramucirumab (IMC-1121B) in Combination With FOLFIRI". The purpose of this study is to assess the effect of concomitant ramucirumab (IMC-1121B) on the pharmacokinetics of irinotecan and its metabolite SN-38 when coadministered with folinic acid and 5-fluorouracil, in participants with advanced malignant solid tumors resistant to standard therapy or for ...
What is the current status of trial NCT01634555?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2012-10. Estimated completion is 2018-02.
What interventions are being tested in trial NCT01634555?
The interventions under investigation include: Irinotecan (DRUG), 5-Fluorouracil (DRUG), Folinic acid (DRUG), Ramucirumab (IMC-1121B) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01634555?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.